
Amgen Reports Positive Phase 3 Data for Subcutaneous Tepezza in Thyroid Eye Disease
As reported on PharmaBiz, Amgen has announced encouraging topline results from a phase 3 clinical trial evaluating a subcutaneous formulation of Tepezza (teprotumumab-trbw) for adults


















